Know what’s really happening at
NewLimit before you sign on.
- On the roadmap
- Longevity Biotech
- AI Drug Discovery
NewLimit is a South San Francisco biotech using partial epigenetic reprogramming to restore aging cells to a more youthful state, starting with liver disease. Co-founded by Coinbase CEO Brian Armstrong, it raised a $435M Series C at a $3.1B valuation to push its first therapy toward human trials.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
NewLimit
- Founded by Brian Armstrong, Blake Byers, and Jacob Kimmel
- 2022
- Series B, May 2025 (~$1.6B valuation)
- $130M
- Series C led by Founders Fund
- $435M
- Post-money valuation on the Series C
- $3.1B
- Planned first human trial, targeting alcohol-related liver disease
- 2027
- Headquarters
- South San Francisco
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Longevity Biotech landscape
- Longevity Biotech growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- NewLimit TAM
- Longevity Biotech market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does NewLimit do
- NewLimit product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- NewLimit customers
- who uses NewLimit
- NewLimit ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- NewLimit competitors
- NewLimit alternatives
- who competes with NewLimit
- NewLimit win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- NewLimit reviews
- NewLimit NRR
- NewLimit churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- NewLimit investment thesis
- NewLimit moat
- bull case bear case
- NewLimit risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- NewLimit ARR
- NewLimit revenue
- NewLimit valuation
- unit economics
Team and culture
Founders, leadership, and org.
- NewLimit founders
- NewLimit CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Based on public reporting and company disclosures as of July 2026.